Zanidatamab  (Synonyms: ZW 25)

Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity^[1].

half-IG G1-kappa/(scFv-kappa-heavy)-h-CH2-CH3

Humanized

Zanidatamab (ZW25) has low nM binding affinity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells with a range of HER2 expression^[1].
Zanidatamab inhibits the growth of human cancer cell lines with a wide range of HER2 expression (5-54% inhibition depending on the cell line), and inhibits ligand-mediated tumor cell proliferation^[1].
Zanidatamab elicits concentration-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to 52% on TNBC cell lines expressing HER2 and exhibits synergy and additivity with multiple chemotherapeutic agents including platins, taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2 expressing tumor cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zanidatamab (ZW25) induces significant tumor regressions, exhibiting 307% tumor growth inhibition relative to hIgG control and a 70% complete regression rate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2169946-15-8

Liquid

Colorless to light yellow

[Zanidatamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3

• 
  Loaded Zanidatamab on AHC2 biosensor, can bind HER2/CD340 Protein, Human (S310Y, HEK293, His, HY-P78680) with an affinity constant of 7.956E-11 M as determined in BLI assay.
• 
  Immobilized Zanidatamab can bind Human Her2/ERBB2 Protein (ECD, His Tag). The EC₅₀ for this effect is 3.09 ng/mL.

• [1]. Weisser N, et, al. Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers. Cancer Res. 2017:77 (13).